Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Herceptin has relatively few side effects, but certainly the one that has troubled us the most is that there is a small, but real, chance of developing heart damage as a consequence of Herceptin, ...

A drug, herceptin, that targets a specific type of breast cancer is about to dramatically change the way doctors treat breast cancer, according to two major new studies.

The breast cancer drug Herceptin prevents breast cancer from coming back in some women, new research shows. Moreover, Herceptin works just as well with and without Adriamycin, a chemotherapy drug ...

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now ...

Mar. 23 -- MONDAY, June 4 (HealthDay News) -- After almost a decade of use, Herceptin continues to prolong the lives of women with a particularly aggressive form of breast cancer. An analysis of ...

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now ...

Herceptin has ushered in a new wave of targeted treatment for breast cancer. In fact, new drugs that target other parts of the HER2 receptor or HER2 chain reaction are already in the works. A drug ...

An aggressive type of breast cancer — a HER2-positive tumor — often shrinks with Herceptin treatment, but side effects can be tough. Researchers say a shorter course of the drug may be a good ...

For Herceptin patients on the medication for five years, the risk of congestive heart failure was 3.8 percent. The rate for patients after three years was 4.1 percent, according to research findings.

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a researcher.